Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $156.50

Abivax SA Sponsored ADR (NASDAQ:ABVX) has received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $156.50.

A number of research firms have commented on ABVX. Wolfe Research set a $136.00 target price on Abivax in a report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research note on Friday, July 17th. Morgan Stanley reiterated an “overweight” rating and issued a $180.00 price target on shares of Abivax in a report on Friday, July 24th. Piper Sandler raised their price objective on shares of Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, Citigroup reissued an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd.

Institutional Investors Weigh In On Abivax

Hedge funds and other institutional investors have recently modified their holdings of the stock. TCG Crossover Management LLC boosted its position in Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after purchasing an additional 1,055,000 shares in the last quarter. UBS Group AG grew its stake in Abivax by 2,561.0% in the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after acquiring an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. grew its stake in Abivax by 0.4% in the 4th quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock valued at $439,714,000 after acquiring an additional 14,000 shares during the last quarter. Morgan Stanley increased its holdings in Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after acquiring an additional 1,681,277 shares in the last quarter. Finally, Vestal Point Capital LP increased its holdings in Abivax by 90.0% during the 4th quarter. Vestal Point Capital LP now owns 1,900,000 shares of the company’s stock valued at $256,224,000 after acquiring an additional 900,000 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Price Performance

Abivax stock opened at $111.73 on Thursday. The stock’s 50 day moving average price is $124.64 and its 200 day moving average price is $118.94. Abivax has a 1-year low of $69.81 and a 1-year high of $148.83. The company has a market cap of $9.75 billion, a PE ratio of -21.45 and a beta of 1.03.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.